Arcus Biosciences, Inc. (RCUS) [Rocket]

In millions, except per share items	Jun-30-23	Jun-05-23	Mar-31-23	Mar-05-23	Jun-30-22	Jun-05-22	Mar-31-22	Mar-05-22
	10-Q	8-K	10-Q	8-K	10-Q	8-K	10-Q	8-K
Revenues
R&D and Commercialization Activities for Zimberelimab	1.0				1.0
Access rights and option continuation periods	9.0		8.0		9.0		8.0
Gilead	7.0		8.0		13.0		16.0
R&D activities for Domvanalimab	1.0		1.0		1.0		1.0
Taiho Collaboration, Access Rights					1.0		2.0
Gilead Collaboration, Access Rights	9.0		8.0		9.0		8.0
Gilead Collaboration, License and R&D services	20.0		17.0		17.0		8.0

Mix
R&D and Commercialization Activities for Zimberelimab	3.4%				3.7%
Access rights and option continuation periods	31.0%		32.0%		33.3%		44.4%
Gilead	24.1%		32.0%		48.1%		89.0%
R&D activities for Domvanalimab	3.4%		4.0%		3.7%		5.6%
Taiho Collaboration, Access Rights					3.7%		11.1%
Gilead Collaboration, Access Rights	31.0%		32.0%		33.3%		44.4%
Gilead Collaboration, License and R&D services	69.0%		68.0%		63.0%		44.4%

Growth
Gilead	-46.2%		-50.1%
Gilead Collaboration, License and R&D services	17.6%		112.5%